InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,303.27
(
0.12%
)
US TECH 100
18,062.00
(
-0.10%
)
Dow Jones
40,003.59
(
0.34%
)
Brent Oil
83.76
(
0.00%
)
Bitcoin
67,026.06
(
-0.08%
)
Post# of 251852
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

jq1234

Send PM Follow Ignore
Followers 68
Posts 4505
Boards Moderated 0
Alias Born 12/13/2009

jq1234

Re: tony111 post# 180660

Wednesday, 07/23/2014 7:36:31 PM

Wednesday, July 23, 2014 7:36:31 PM

Post# of 251852
>> Targeting EGF-1 might be an added benefit but it also reduces MTD and reduces HER-2 inhibition.

We are not talking about single agent here. Even if we do, oncology has been obsessed with MTD, resulting so many small companies with unnecessarily high so-called MTD - it is over rated for target agents especially in combination with similar agents, mechanism is more important than so-called MTD.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up